Paul A. Adams, M.D. Emergency Medicine Matthew P. Allinder, M.D. Emergency Medicine Austin C. Baker, M.D. Emergency Medicine Jared S. Bass, D.O. Emergency Medicine Shannon M. Becht, M.D. Emergency Medicine Kristen Bublitz, D.O. Emergency Medicine Victoria Buescher, M.D. Internal Medicine Richard D. Carlisle, M.D. Emergency Medicine Gang Cheng, M.D. Cardiology Charlotte R. Crowley, M.D. Emergency…
After completing a pair of spinal fellowships in the latest surgical techniques and technologies, Shawn W. Adams, M.D., has joined Norton Leatherman Spine and Norton Neuroscience Institute. Dr. Adams’ fellowships covered complex adult spine, deformity and minimally invasive techniques. “I try to develop a relationship with my patients and partner with them to get the…
George Gad, M.D. Hospital Medicine Nathan Gonda, D.O. Emergency Medicine Sarah B. Radtke, M.D. Obstetrics/ Gynecology Lauren M. Strait, M.D. Vascular Surgery Molly E. Tuller, M.D. Obstetrics/Gynecology Tracey D. Wolford, M.D. Gastroenterology Maureen Carberry, PA-C Colon and Rectal Surgery Caitlin C. Crowley, PA-C Pulmonology Emily Mathews, PA-C Emergency Medicine Felecia Q. Carey, APRN Urgent Care…
Recently approved Tzield (teplizumab-mzwv), is delivering breakthrough results that suggest it may delay the onset of Stage 3 Type 1 diabetes by an average of two years. The first-in-class drug is approved for adults and children ages 8 and older with Stage 2 Type 1 diabetes. “Delaying the onset of Stage 3 not only postpones…
Afrezza inhaled insulin, currently approved for adults, is being tested for children in a clinical trial at Wendy Novak Diabetes Institute, a part of Norton Children’s Endocrinology, affiliated with the UofL School of Medicine. Norton Children’s is one of 40 sites nationally participating in the Phase 3 trial. Afrezza is an ultra-fast-acting inhaled mealtime insulin,…
Researchers are recruiting pediatric medulloblastoma patients for a novel use of difluoromethylornithine (DFMO) to prevent relapse. The multisite study, sponsored by the Beat Childhood Cancer Consortium and led by Michael Angelo C. Huang, M.D., pediatric neuro-oncologist at Norton Children’s Cancer Institute, affiliated with the UofL School of Medicine, looks at whether DFMO offers a new…
Butyrate-producing gut bacteria are a promising target for preventing and treating memory loss associated with Alzheimer’s disease, according to research presented recently at the Alzheimer’s Association International Conference (AAIC) in Amsterdam, Netherlands. The research in 3XTg mouse model demonstrated that oral administration of tributyrin mitigates age-associated loss of butyrate-producing bacteria and prevents the decline in…
Surgeons face two choices for infants with critical left heart obstruction who have had prior hybrid palliation: a Norwood operation or a comprehensive stage II (COMPSII). The critical left heart obstruction cohort of the multi-institutional Congenital Heart Surgeons’ Society looked at patient characteristics and outcomes for these two pathways. The study, “Norwood Operation Versus Comprehensive…
A human Phase 1 immunotherapy clinical trial is underway using natural killer cells, or NK cells, to target relapsed or refractory acute myeloid leukemia. Acute myeloid leukemia patients who have exhausted other treatment options are potential candidates for the trial, ClinicalTrials.gov ID NCT05470140. The trial uses cytokine-reprogrammed, non-engineered, “off-the-shelf” NK cells from a healthy donor….
Jonathan P. Boland, M.D. Emergency Medicine James C. Gray IV, M.D. Emergency Medicine Stephanie Miles, M.D. Family Medicine Vladimir Pulgaron, M.D. Family Medicine Steven J. Radtke, M.D. Urogynecology Cindy Truong, D.O. Internal Medicine Michael McCool II, PA-C Neurosurgery Alexandria J. Bassler, APRN Thoracic Surgery Tracy C. Jensen, APRN Internal Medicine Whitney L. King, APRN Cardiology…
The 28th Gail Klein Garlove Lectureship on Nov. 1 is titled “Advancing Precision Medicine Through New Discoveries and Technologies,” and will be presented by Sameek Roychowdhury, M.D., Ph.D., medical director of the cancer genomics laboratory and medical oncologist at The Ohio State University Comprehensive Cancer Center – James. The event is hosted by Norton Healthcare…
At some point in their life, 1 in 8 women will develop breast cancer. Approximately 20% of breast cancer cases are familial, affecting two or more women in the same family, usually at a later age. An estimated 5% to 10% of breast cancers are caused by a genetic mutation, called hereditary breast cancer. Red…